A Study of Vesicles, Prostate Cancer

Overview

About this study

The purpose of this study is to address the critical gap in prostate cancer management by rigorously evaluating and validating prostate cancer-derived extracellular vesicles (PC-EVs) and circulating tumor DNA (ctDNA) across time and treatments.
 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

-    Histological confirmation of metastatic prostate cancer (priority) or genitourinary malignancy
-    ECOG Performance Status (PS) 0, 1 or 2 
-    Provide written informed consent 
-    Willingness to provide blood specimens for correlative research
-    Willingness to provide tissue specimens for correlative research

Exclusion Criteria:

 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/19/2024. Questions regarding updates should be directed to the study team contact.

 

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jacob Orme, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions